NEW YORK (GenomeWeb News) – Life Technologies today announced a commercialization deal covering three stem cell technologies from Cellular Dynamics International for the consistent development and growth of human iPS cells for research and bioproduction.

Life Tech will commercialize CDI's Essential 8 Medium, Vitronectin, and Episomal iPSC Reprogramming Vectors, which together address several challenges associated with developing relevant cells, the Carlsbad, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.